Investor Newsletter

Issue 04 2018

MicroPort®

MicroPort® Completes the Acquisition of the Cardiac Rhythm Management Business from LivaNova

MicroPort Scientific Corporation (HK: 00853) ("MicroPort®") announced the closing of the transaction to acquire the Cardiac Rhythm Management ("CRM") Business from LivaNova PLC (NASDAQ:LIVN) ("LivaNova"). Upon completion of the acquisition, the acquired CRM Business is now officially rebranded as MicroPort® CRM. This acquisition is expected to establish MicroPort® CRM as the fifth largest CRM business in the world and make MicroPort® the most advanced domestic company in China with CRM know-how in the global CRM market.

The CRM Business Franchise develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failures, with more than one million patients implanted globally over nearly four decades. The CRM Business generated approximately US$246 million in revenue in 2017 and had over 900 employees with operations in Clamart, France; Saluggia, Italy; Santo Domingo, Dominican Republic.

"The CRM business is a key driver for MicroPort®'s future growth and has a robust pipeline with great potential in the global CRM market," said Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort®, "We are committed to investing in the business to realize the full potential of its product pipeline and look forward to developing new, innovative solutions, with the purpose to serve more patients and thereby eventually earn a top ranking market share that the CRM technologies well deserve."



MicroPort

Mr. Jonathan Chen Promoted to Chief International Business Officer of MPSC

MicroPort® ("MPSC") is pleased to announce that effective immediately Mr. Jonathan Chen has been promoted to Chief International Business Officer of MPSC. Mr. Jonathan Chen joint in MPSC in July of 2012, and originally served as the Executive Vice President of International Operations and Investor Relations of MPSC. He has become the Chairperson of MPSC's Intercontinental Executive Committee ("IEC") since September, 2015. Mr. Chen's primary responsibilities include growing the company's International business in markets outside of China, primarily in the markets of the U.S, Europe and South America.

Mr. Chen has over 21 years of experience in the medical device industry. Prior to joining the company, Mr. Chen worked for Angiotech Pharmaceuticals, Inc. for six years, where he was Senior Vice President of Business Development. Prior to joining Angiotech, Mr. Chen was a life sciences investment banker for Credit Suisse and Alex. Brown & Sons. He advised on over $3 billion in Mergers & Acquisitions transactions. Mr. Chen has a Bachelor of Arts degree in Economics and a Bachelor of Sciences degree with honors in Biological Sciences from Stanford University.

MicroPort® Orthopedics Holds China-Australia Medial Pivot Knee Seminar

Recently, MicroPort® Orthopedics invited Dr. Warwich Bruce of Concord Clinical School of the University of Sydney for China-Australia Medical Pivot Knee Seminar. Dr. Warwich Bruce introduced the design rational and application of the medial pivot knee to Chinese surgeons. As an Australian hip and knee orthopedic surgeon, Dr. Warwick Bruce worked on the study and application of medial pivot knee for two decades. He shared his understanding of the design concept of MicroPort® orthopedics medial pivot knee and performed a surgery in application of medial pivot knee in the total knee arthroplasty with Chinese orthopedic surgeons. The success of the surgery showed that medial pivot knee can not only be applied to gen varum patients but also genu valgum patients.

MicroPort® Orthopedics Medial Pivot Knee was launched in the US in 1998 with around 20 years' clinical history. Up to date, nearly 550,000 Medial Pivot Knees have been implanted globally. Several long-term studies have proved the advantages of medial pivot knee in total knee arthroplasty ("TKA"). The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.

MicroPort® Orthopedics Medial Pivot Knee is gaining higher recognition among surgeons and patients due to its unique design. This workshop aims to provide a professional academic platform for overseas orthopedic experts. In the future, MicroPort® Orthopedics will invite more overseas experts to come to China for academic exchange, and jointly push the development of knee replacement, to provide more safe and effective medical solutions to improve patients' life quality.



MicroPort® Hosts the Investigator Meeting for Firehawk® TARGET DAPT Trial

MicroPort® hosted the First Investigator Meeting for the pivotal clinical study TARGET DAPT Trial of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), a key study on shortening the duration of dual antiplatelet therapy ("DAPT") after DES implantation in patients undergoing percutaneous coronary intervention ("PCI"). Around 34 investigators from 30 sites attended the meeting.

The TARGET DAPT clinical study is a prospective, multi-center, randomized controlled clinical under the leadership of Academician Ge Junbo of Zhongshan Hospital of Fudan University. This trial aims to assess the safety and effectiveness of three-month versus 12-month dual antiplatelet therapy in patients undergoing PCI with Firehawk® implantation. The study plans to enroll about 2500 subjects in around 40 hospitals in China.

During the meeting, Professor Feng Zhang of Zhongshan Hospital introduced the protocol of TARGET CTO study, and specified that the Silber score for TARGET DAPT clinical trial reached 9 out of 10 points, which signified that it is a highly scientific and rigorous clinical trial.

The clinical results of Firehawk® on TARGET I RCT and TARGET AC provided strong theoretical basis for shortening the duration of dual antiplatelet therapy after DES implantation in PCI patients. According to our calculation, if we assume shortening the duration of DAPT to three months after DES implantation is safe, then it will save 4.8 billion yuan medical cost for patients and the government compared with the need for standard dual antiplatelet therapy, based on the number of 700,000 PCI cases in the whole country in 2017.

MicroPort® will continue to advance the robust series clinical research program globally, and it is expected that Firehawk® FDA IDE clinical trial will gain FDA approval in the near future. With the support of increasingly more clinical data, Firehawk® is demonstrated to have the potential to reduce the duration of dual antiplatelet therapy after stent implantation, lower the risk of bleeding from long-term dual antiplatelet therapy in patients with high bleeding risk, and cut the medical costs, to bring benefit to more patients with coronary heart diseases worldwide.

MicroPort

MicroPort® CardioFlow Attends Fourth China Valve (Hangzhou) Meeting

MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") attended the Fourth China Valve (Hangzhou) Meeting. Since its first use in 2002, transcatheter aortic valve replacement ("TAVR") has revolutionized the cardiovascular industry. Academician Junbo Ge of Zhongshan Hospital of Fudan University introduced the design rationale of VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®") and released the one-year follow-up result of VitaFlow® which showed that the occurrence of all-cause mortality is as low as 2.7%, and there is no major stroke. All of the patients reported good hemodynamic function, no moderate or severe PVL.

During the meeting, Academician Ge also gave a report on the future development of VAVR. He said, the ultimate goal of TAVR is All Comes TAVR, which means the technique will allow anyone who suffers from aortic valvular diseases and needs medical treatment to receive TAVR, no matter how risky the disease is, how the anatomy is, and how old the patient is. In the recent 10 years, TAVR technologies have been experiencing fast development, and the new generation aortic valve has caught wide attention from the industry. In this meeting, several professionals visited MicroPort® CardioFlow booth and showed great interest in VitaFlow® and its promising future development.



MicroPort

Tubridge® Successfully Completes the First Post-Marketing Clinical Transplantation

In April 2018, after gaining the approval of China Food and Drug Administration ("CFDA"), the first clinical transplantation of Tubridge® Vascular Reconstruction Device ("Tubridge®") has successfully completed in Henan, China. Tubridge® is a neurovascular intervention product developed by MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"). It gained CFDA approval in March 2018 and it is the only domestic flow diverting stent that has obtained CFDA approval.

Tubridge® is the first China-developed flow diverting stent that has obtained CFDA approval in China. It is designed for the treatment of large and giant cerebral aneurysm. The device cures the cerebral aneurysm by effectively diverting the blood flow based on the hemodynamics, reducing the impact of blood flow to the cerebral aneurysm, and enabling the endothelial cells to grow along the stent struts and gradually repair aneurysmal neck.

MicroPort® NeuroTech Holds Intracranial Vessel Endovascular Exclusion Technique Summit Forum



MicroPort® NeuroTech hosted Intracranial Vascular Endovascular Repair Summit in Shanghai and invited several neuro-interventional experts to share opinion in WILLIS® Intracranial Stent Graft System ("WILLIS®") by lectures and case studies.

WILLIS® is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China. It is also the first medical device to achieve complete vascular reconstruction in China. WILLIS® vascular reconstruction achieves complete occlusion, and unlike traditional treatment using stent-assisted coil embolization, WILLIS® effectively shunts the blood flow and keeps it off of the aneurysm wall.

During the summit, experts had hot discussions regarding indications and techniques of WILLIS®. The excellent performance of WILLIS® won recognition of all the physicians in attendance. Zhiyong Xie, President of MicroPort® NeuroTech, said: "We have been hosting such summit for several years, by which we aim to build a platform for academic exchange and medical education, to jointly promote the development of cerebrovascular endovascular exclusion techniques."

MicroPort® NeuroTech Attends 15th CFCVD

MicroPort® NeuroTech attended the 15th China Forum of Cerebrovascular Diseases ("CFCVD") held in Beijing. The CFCVD is one of the most premier academic events in China's cerebrovascular diseases field, covering intracranial stent, arterial aneurysm, AVM, carotid artery lesion, thrombectomy, severe case treatment, nursing, and other interventional and surgical treatment of cerebrovascular diseases.

In the session of arterial aneurysm, Professor Xiaodong Xie gave a presentation on safety and efficacy of WILLIS® Intracranial Stent Graft System ("WILLIS®"). Researched and developed independently by MicroPort® NeuroTech, WILLIS® is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China, and also the first medical device to achieve complete vascular reconstruction in China. WILLIS® vascular reconstruction achieves complete occlusion, and unlike traditional treatment using stent-assisted coil embolization, WILLIS® effectively shunts the blood flow and keeps it off of the aneurysm wall. Based on his clinical cases in West China Hospital, Professor Xie spoke highly of the excellent performance of WILLIS®.

MicroPort® NeuroTech also displayed its innovative product - Tubridge® Vascular Reconstruction Device, that was newly granted the approval from China Food and Drug Administration ("CFDA"), which attracted a lot of attendees to inquire for product information. Tubridge® is the first China-developed intracranial stent with densely meshed wire braids. It is designed for the treatment of large and giant cerebral aneurysm. The clinical performance of Tubridge® gained high recognition from experts in attendance and they expressed their expectation on its future clinical application.



MicroPort

MicroPort® Endovascular Attends the 7th Edition of Pangu Aortic Disease Forum

MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Seventh Pangu Aortic Disease Forum and co-organized a Youth Forum during the event. This year's Pangu Aortic Disease Forum gathered many renowned domestic experts in the cardiac vessel field to discuss about the latest clinical achivements and study outcome related with the treatment of aortic diseases.

The forum discussed the topics like “application of Fontus™ Branched Stent Graft in Surgical Operation" and "The application of Castor® Branch Aortic Stent-Graft System ("Castor®") for the treatment of complicated Type B aortic dissection", and introduced the establishment of Sun's procedure, a surgical procedure of using CRONUS™. On the basis of the morphology of the aortic diseases in China as well as the design features of CRONUS™, the four branches artificial artery replacement and elephant trunk technique was created by Professor Lizhong Sun of Beijing Anzhen Hospital. Thanks to CRONUS™ and Sun's Procedure, the death rate of Type A aortic dissection is reduced to 5% from 20%, the rate of false lumen occlusion is improved to nearly 100% from 40%, and the rate of reoperation is declined to 10% from 30%. According to statistics, from 2003 to 2018, over 30,000 CRONUS™ stents were implanted with the promotion of Sun's procedure.

Zhenghua Miao, President of MicroPort® Endovascular, said: "Since its market launch 15 years ago, CRONUS™ has made great contributions to simplifying vascular surgeries, increasing surgical success rate and improving patients' postoperative recovery. MicroPort® Endovascular primarily focuses on R&D, and manufacturing support of the interventional medical devices, including AAA/TAA stent graft systems, surgical stent graft system, aortic balloon dilation catheter and peripheral vascular stents/balloons. It will continue to strive for innovation and product diversification, to help promote the development of China's aortic surgical technique."

MicroPort

MicroPort® Endovascular Attends Eighth China Vascular Surgery and Endovascular Treatment & Complication Prevention and Treatment Forum

MicroPort® Endovascular attended the Eighth China Vascular Surgery and Endovascular Treatment & Complication Prevention and Treatment Forum that focused on the latest development and hot issues of vascular surgery by expert lectures, keynote speeches, as well as debates and discussions, covering drug therapy, radiographic diagnosis, complications and misdiagnosis of open surgery and endovascular therapy in the vascular surgery department. In the meeting, MicroPort® Endovascular displayed several innovative products such as Minos™ Ultra Low-Profile AAA Stent-Graft System, which attracted wide attention from the audience.

In the meeting, Professor Junjie Zou of Jiangsu Province Hospital delivered a speech about an endovascular treatment for an abdominal aortic aneurysm combined with external iliac artery occlusion, in which he shared the clinical advantages of Minos™ Ultra Low Profile AAA Stent-Graft in-house developed by MicroPort® Endovascular. Minos™ Stent-Graft has unique advantages in treating heavily tortuous anatomy, short neck and narrow access arteries as low as 5mm diameter. On Aril 1, 2017, Minos™ Ultra Low-Profile AAA Stent-Graft System was granted to enter the special Green-Path by China Food and Drug Administration ("CFDA"), rapid-track of review and approval procedure for innovative medical devices, which will significantly expedite its approval time.

MicroPort® Endovascular Awarded "2017 Shanghai Brand Cultivation Demonstration Enterprise"

MicroPort® Endovascular was awarded "2017 Shanghai Brand Cultivation Demonstration Enterprise" by Shanghai Municipal Commission of Economy and Information. Shanghai Municipal Commission of Economy and Information initiated the selection of Brand Cultivation Demonstration Enterprise aiming to cultivate a group of enterprises with independent brand and international competitiveness. Companies winning the title are mostly industry leaders with good brand image. The applicants will be strictly screened by government authorities based on their social awareness, industry position, innovative ability, and etc. The applicants have to go through several rounds of review before they win the title of "Shanghai Top Brand". Only companies with independent intellectual property, strong probability and competiveness are qualified to apply for the selection.

MicroPort® Endovascular has always been striving for innovation to promote the development of independent brands. As it is selected as this year's "Shanghai Brand Cultivation Demonstration Enterprise" it demonstrated the increasing brand awareness of MicroPort® Endovascular with its leading position in terms of product quality and company governance. In the future, MicroPort® Endovascular will continue to carry out the management credo of "Eyes for Greatness, Hands on Details" to offer cost-effective medical solutions to save or reshape lives or improve the quality of life for patients in China and worldwide.

MicroPort

MicroPort® Attends SCC 2018

MicroPort® attended the 20th South China International Congress of Cardiology ("SCC 2018") and hosted a case competition. Themed on "Science, Cooperation, Innovation", the SCC 2018 invited domestic and overseas cardiologists to exchange ideas.

In this conference, MicroPort® hosted three case competitions involving 18 cases in total. MicroPort® invited 15 renowned experts to serve as moderators. Since 2016, MicroPort® hosted the case competition in various national-level congresses and has received positive feedback. It was the third time for MicroPort® to host such seminar in the CCIF, which fully demonstrated the excellent performance of its stents. Meanwhile, this case competition was live broadcasted via Dr. King studio and MicroPort® online platform, which attracted more than 1,500 audience to watch online. It provided opportunities for physicians in rural areas to learn more advanced technologies.

During the conference, MicroPort® and MicroPort® EP set up a booth to display several innovative products such as Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Columbus™ 3D EP Navigation System ("Columbus™"), attracting many attendees to pay a visit and inquire for product information. After trying out Columbus™ and its matching catheter FireMagic™, some experts in attendance showed high recognition in their stability and reliability. Meanwhile, MicroPort® carried out satisfaction survey activities during the conference. Experts spoke highly of MicroPort®'s cardiovascular products such as Firehawk® and Firebird2® and offered suggestions regarding the product R&D.



Foreign Experts Visit MicroPort® During CIT 2018

Over a hundred experts from Asian Pacific and Latin American countries visited MicroPort® during the CIT 2018 which was held in Suzhou, China.

Jonathan Chen, Chief International Business Officer, extended a welcome speech to the experts while they visited the MicroPort® headquarters in Shanghai. Jonathan Chen made an introduction of the company development history, business sectors and blueprint, highlighting its global development strategy and international business development. Dr. Costantino R. Costantini, Dr. Alfredo Rodriguez, Dr. Lee Kang-yin Michael, and Dr. Tam Li-wah received interviews from MicroPort®'s internal publication MicroPort® Review on the prospects of the coronary intervention and the challenges in this field. They highly recognized the contribution that MicroPort® had made in providing high-quality solutions to cardiovascular patients.

The experts wrote down their wishes for MicroPort® after reviewing its 20 years of growth and development. Jonathan Chen thanked them for their supports. In the future, MicroPort® will continue to strive for innovation and provide platforms for clinicians and enterprises to strengthen mutual communication and cooperation to help develop more innovative products and technologies to benefit more patients.

MicroPort

Investor Newsletter

Issue 04 2018

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com